U.S. Markets closed

Surmodics, Inc. (SRDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.23+0.30 (+0.81%)
At close: 04:00PM EDT
37.23 0.00 (0.00%)
After hours: 04:02PM EDT

Surmodics, Inc.

9924 West 74th Street
Eden Prairie, MN 55344-3523
United States
952 500 7000

IndustryMedical Devices
Full Time Employees389

Key Executives

NameTitlePayExercisedYear Born
Mr. Gary R. MaharajCEO, Pres & Director1.29M2.59M1963
Mr. Timothy J. ArensSr. VP of Fin. & Information Technology and CFO572k857.12k1967
Mr. Gordon S. WeberSr. VP of Legal, Gen. Counsel & Sec.573.67kN/A1963
Ms. Teryl L. W. SidesSr. VP of Product Devel. & Chief Marketing Officer638.67kN/A1970
Mr. Joseph J. StichSr. VP and GM of HR & In Vitro Diagnostics570.92k501.23k1965
Mr. John D. MandersCorp. Controller & Principal Accounting OfficerN/AN/A1981
Mr. Charles W. OlsonSr. VP of Commercial & Bus. Devel. of Medical DevicesN/AN/A1964
Mr. Gregg S. SuttonVP of R&D - Medical DevicesN/AN/A1960
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Corporate Governance

Surmodics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.